Description: Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Home Page: www.inflarx.de
IFRX Technical Analysis
Winzerlaer Str. 2
Jena,
07745
Germany
Phone:
49 3641 508 180
Officers
| Name | Title |
|---|---|
| Dr. Niels C. Riedemann M.D., Ph.D. | Co-Founder, CEO & Exec. Director |
| Prof. Renfeng Guo M.D. | Co-Founder, Chief Scientific Officer & Exec. Director |
| Dr. Thomas Taapken Ph.D. | Chief Financial Officer |
| Ms. Nicole Bertsch | Sr. Director & Head of HR |
| Dr. Maria Habel PH.D. | Head of Preclinical R&D |
| Ms. Evelyn Roth-Geissler Ph.D. | VP & Head of Clinical Operations |
| Dr. Bruce P. Burnett Ph.D. | VP & Head of Medical Affairs |
| Mr. Christian Schmid | VP and Head of Legal Affairs & Corp. Counsel |
| Mr. Kafi Boaten | Sr. Director and Head of Supply & Clinical Trial Supplies |
| Mr. Peter Hurt Ph.D. | Sr. Director and Head of Drug Safety & Pharmacovigiliance |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9727 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-11-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |